Study of Cerebrolysin for Treatment of Infants With History of Neonatal Hypoxic Ischemic Encephalopathy
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether nerve growth factor (cerebrolysin®) therapy
will improve the psychomotor outcome in infants with moderate and severe hypoxic ischemic
encephalopathy after hospital discharge.